Previous 10 | Next 10 |
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42 nd Annual J.P. Morg...
2023-12-28 20:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-21 08:00:00 ET Summary The U.S. Court declares United Therapeutics' PAH treatment patent unpatentable, favoring Liquidia in the market. Liquidia's modest revenue increase and high R&D and G&A expenses lead to a wider net loss. Liquidia has strong short-term liq...
2023-12-20 12:00:32 ET Summary Liquidia Corporation is worth at least $15 in a win. Roivant Sciences is worth at least $12 per share. Burford Capital Limited is worth at least $20 per share. Value & Event Driven Investing I recently spoke for a half an hour a...
2023-12-20 09:54:22 ET More on Liquidia Liquidia Corporation (LQDA) Q3 2023 Earnings Call Transcript Liquidia prices equity offering Liquidia gains as court sets December date for hearing in patent dispute Seeking Alpha’s Quant Rating on Liquidia ...
2023-12-18 12:05:08 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Be Cautious Of High Valuations Top stocks with earning stability and quality + overweight - MS Morgan Stanley: Dividend paying stocks > non-dividend paying stocks, since 2000 Seeking ...
United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“ Merger Sub ”), has successfully completed the previously announced tender...
United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“ Merger Sub ”), a wholly owned subsidiary of United Therapeutics, to acquire all...
2023-12-10 10:41:03 ET Summary Today, we take a deeper look at United Therapeutics Corporation, whose shares are cheap but the company does have litigation concerns. The company's treprostinil products are also facing challenges from generics and clinical aspirants, and its growth...
United Therapeutics (Nasdaq: UTHR ), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2024 . This award is presented by Newsweek and Statista Inc., the world-leading statistics po...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. ...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...